logo
Plus   Neg
Share
Email
Comment

Novartis Says Secukinumab Is Superior To Enbrel In Psoriasis, Meets Endpoints

Swiss drug maker Novartis AG (NVS) Monday announced that a Phase III study of psoriasis drug secukinumab or AIN457 showed that it is superior to Enbrel or etanercept and that it met all primary and secondary endpoints.

The healthcare products major noted that in a head-to-head Phase III psoriasis study, secukinumab was superior to Enbrel in clearing skin. Enbrel is an anti-tumor necrosis factor or anti-TNF therapy.

According to Novartis, Fixture, a pivotal trial for registration, was a randomized, double-blind, double-dummy, placebo controlled, multicenter global study of subcutaneous secukinumab in moderate-to-severe plaque psoriasis involving 1,307 patients.

Fixture trial is the full year investigative eXamination of secukinumab against eTanercept using 2 dosing regimens to determine efficacy in psoriasis. The study was to establish treatment measures and assess the efficacy of secukinumab, including Psoriasis Area and Severity Index 75, or PASI 75 and the Investigator's Global Assessment, a standard tool to assess the clearing of skin after treatment.

The firm noted that in the Fixture study, the observed safety profile of secukinumab was consistent with previously reported results from Phase II studies in moderate-to-severe plaque psoriasis and no new safety concerns were identified.

Tim Wright, Global Head of Development, Novartis Pharmaceuticals stated, "With 40-50% of people living with moderate-to-severe plaque psoriasis dissatisfied with their current therapies, there is clearly an unmet medical need for new therapies that act faster and longer to relieve pain, itching and other symptoms."

The company said regulatory submissions for secukinumab, a therapy targeting IL-17A, are on track for the second half of 2013. Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes IL-17A, a key pro-inflammatory cytokine.

The full results from the secukinumab Phase III study are likely to be presented at major medical congresses later this year.

Separately, Novartis said it has signed a development and licensing agreement with Biological E Ltd. or BioE, an Indian biopharmaceutical company, for two vaccines to protect against typhoid and paratyphoid fevers.

As part of the the license, the Novartis Vaccines Institute for Global Health or NVGH would transfer technology to BioE, which would have financial and operational responsibility for manufacturing, further clinical development, approval and distribution in the developing world.

NVS closed Friday's regular trading at $70.72 on the NYSE.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
BlackRock Inc., the world's largest asset manager, said it plans to speak with gun makers and distributors following public outcry after the Florida high school shooting that killed 17 people. BlackRock, which had $6.3 trillion in assets under management as of December 31, 2017, holds shares in gun makers Sturm Ruger & Co. Inc. as well as American Outdoor Brands Corp. An upgraded boarding in Southwest Airline will cost you more. The airline usually not assign seats to passengers, but one can choose from an open seat. The Upgraded Boarding will allow passengers to choose from A1 - A15 boarding positions. The cost for these positions would be $30, $40 and $50, depending on flight and route. This option can be availed from the ticket counter or gate. Citigroup Inc.'s co-head of mergers and acquisitions, Peter Tague, is leaving the company, according to media reports, citing people familiar with the matter. Tague has been co-head of Global M&A business at Citigroup since March 2012, alongside Cary Kochman and Mark Shafir. It was not immediately clear what Tague intends to do after he leaves Citigroup.
comments powered by Disqus
Follow RTT